MRNA · earnings call history
Moderna Q1 FY26 — Strong Revenue Growth and Pipeline Advancement
Read the briefModerna Q4 FY25 — Strong mNEXSPIKE Launch and Cost Reduction
Read the briefModerna Q3 FY25 — Strong Cost Reduction and mNEXSPIKE Uptake
Read the briefModerna Q4 FY24 — Strong Cash Position and Pipeline Progress Amidst Revenue Decline
Read the briefBrowse all US companies on the earnings-call register.